SECURITY AGREEMENT among OREXIGEN THERAPEUTICS, INC., as Issuer, and THE GUARANTORS PARTY HERETO FROM TIME TO TIME, as Guarantors and U.S. BANK NATIONAL ASSOCIATION, as Collateral Agent Dated as of March 21, 2016Security Agreement • March 25th, 2016 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • New York
This SECURITY AGREEMENT, dated as of March 21, 2016 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time in accordance with the provisions hereof, including by one or more Joinder Agreements, or otherwise, this “Agreement”), is made by and among Orexigen Therapeutics, Inc., a Delaware corporation (“Issuer”), and the Subsidiaries of Issuer from time to time party hereto by execution of a Joinder Agreement (the “Guarantors”), as pledgors, assignors and debtors (Issuer, together with the Guarantors, in such capacities and together with any successors in such capacities, the “Pledgors,” and each, a “Pledgor”), and U.S. Bank National Association, a national banking association, solely in its capacity as collateral agent pursuant to the Indenture, as pledgee, assignee and secured party (in such capacities and together with any successors in such capacities, the “Collateral Agent”).
OREXIGEN THERAPEUTICS, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee and Collateral Agent INDENTURE Dated as of March 21, 2016 0% Convertible Senior Secured Notes due 2020Indenture • March 25th, 2016 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • New York
INDENTURE dated as of March 21, 2016 between OREXIGEN THERAPEUTICS, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK NATIONAL ASSOCIATION, a national banking association organized and existing under the laws of the United States of America, as trustee (in such capacity, the “Trustee,” as more fully set forth in Section 1.01), collateral agent (in such capacity, the “Collateral Agent,” as more fully set forth in Section 1.01) Note Registrar, Paying Agent and Conversion Agent.
